Companies
Comprehensive database of innovative Biophama companies in Korea
BQURA Company Database
Find out most innovative Korean Biopharma companies
테스트
Xcell Therapeutics
BiotechXcell was established in September 2015 and is engaged in the research, development, and production of cell culture media suitable for advanced biopharmaceuticals (CGT). Based on ACF essential, it has built a cell-customized media development platform technology by incorporating significance scoring data for candidate ingredients specific to different cell types and the know-how gained from the media development process. The company's media development and manufacturing technology has been recognized as a core strategic technology in the "Key Cell and Material Manufacturing Technology for Advanced Biopharmaceutical Production" field by the Ministry of Trade, Industry, and Energy.
S.BIOMEDICS
BiotechS.BIOMEDICS develops therapies using a variety of cells, including somatic cells, immune cells, adult stem cells, and embryonic stem cells. It also manufactures and sells CFC-FECS-DF (a cosmetic ingredient). The company owns Esthefarm, a subsidiary that specializes in the manufacturing and sales of skincare products.
GENEONE Lifescience
BiotechA biopharmaceutical company dedicated to the research, development and contract manufacturing of nucleic acid-based biopharmaceuticals, including DNA and RNA vaccines, and to the development of novel small molecule therapeutics.
Hanall Biopharma
Pharma, BioThe company produces and sells around 160 specialized and general medicines based on a diverse portfolio that includes the endocrine, circulatory, and urinary systems. Since 2004, it has built an R&D infrastructure by securing key research personnel and expanding research facilities through corporate innovation in global new drug R&D. It is currently researching Anti-TNF biopharmaceuticals and new target anticancer immunotherapeutic antibodies that strengthen the body's anticancer immune response to treat cancer.
Ensol Bioscience
BiotechAs a bio big data-based biopharmaceutical company that develops global innovative new drugs for diseases without therapeutic alternatives worldwide, such as degenerative disc, degenerative arthritis, TNBC, Alzheimer’s disease and type 1 diabetes, Ensol Biosciences applies bio big data-based BT/IT convergence technology from the aspects of drug efficacy, mechanism and toxicity, and side effects to develop outstanding drugs with high potential, and works on various discoveries and clinical trial phases systematically.
QURIENT
BiotechFounded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network. Qurient mainly engages in value creation between early discovery to clinical proof-of-concept. The particular concentration in the value chain creates more efficient organizational structure with clear focus on innovation. Qurient believes late stage development is better handled by fully integrated pharmaceutical/biotech industry with proper marketing function in the therapeutic area. Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders.
G2GBio
BiotechG2GBIO is addressing this challenge by advancing treatments for chronic diseases through our proprietary InnoLAMP (Innovative Long-Acting Microsphere Platform) technology. We are very proud that our unique approach ensures the production of high-quality, uniform microsphere injectables on a commercial scale. With InnoLAMP, G2GBIO is well-positioned to expand globally and continuously innovate, aiming to bring new, effective drugs to the market.
ADEL
BiotechAdel is a company founded in 2016 by Professor Seung-Yong Yoon from the Department of Neuroscience at Ulsan College of Medicine, Seoul Asan Hospital, to develop new drugs and diagnostic biomarkers for neurodegenerative diseases, including Alzheimer's disease. The company plans to allocate the recent investment funds to advance the Phase 1 clinical trial of ADEL-Y01, a tau antibody candidate for the treatment of Alzheimer's dementia, currently underway in the United States. In September last year, Adel received approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1a and 1b trials to assess the safety and tolerability in humans. ADEL-Y01 is the world’s first antibody candidate that specifically targets acetylated tau (tau-acK280), a disease-specific variant associated with dementia, without affecting normal tau. The company also plans to use the investment to further the preclinical research and development of its subsequent drug pipeline, including the APOE4 antibody (ADEL-Y04). Additionally, Adel is developing other drug candidates targeting various proteins and a platform technology for Target Protein Degradation.
Rznomics
BiotechRznomics Inc. is a biotech company founded by Professor Seong-Wook Lee at Dankook University in August 2017. Rznomics develops RNA based gene therapies for cancers and intractable diseases. The excellence of the Rznomics’ technology has been acknowledged for being selected as a national new drug development project organized by the Ministry of Health and Welfare, TIPS program organized by the Small and Medium Business Administration, and innovative new drug pipeline discovery project organized by the Ministry of Science and ICT.
BIO DESIGN LAB
etcAt Bio Design Lab, we redefine the development of biopharmaceuticals through our innovative systems-level genetic and genomic design-based strategies. Unlike conventional methods that modify single components of complex bio-entities—often resulting in unforeseen serious side effects—we view biopharmaceuticals as intricate systems with interconnected biomolecular components.
ALTOS Biologics
BiotechAltos Biologics, a subsidiary of the South Korean biotechnology firm Alteogen Inc., is a company focused on the development and commercialization of biosimilars. One of the company’s flagship products is ALT-L9, a biosimilar to the macular degeneration treatment Eylea® (aflibercept). ALT-L9 has successfully completed a global Phase III clinical trial, which involved over 400 participants across 12 countries. On July 1, 2024, Altos Biologics submitted a Marketing Authorization Application for ALT-L9 to the European Medicines Agency.